Astellas and Pfizer

Grants will be awarded for independent CME/CE-certified education designed to enhance understanding of the management of hormone sensitive prostate cancer (HSPC), to address gaps related to treatment intensification of mHSPC given the numerous randomized trials that have demonstrated benefit in this space. Proposals should leverage innovative data and content delivery mechanisms including an omnichannel approach. Knowledge gaps in earlier stage prostate cancer research that have been identified in the public healthcare landscape include: knowledge of treatment options in HSPC, including treatment intensification and availability of life-prolonging therapies in mHSPC; barriers to treatment intensification in mHSPC; impact of early treatment on subsequent therapeutic options; integration of NCCN Prostate Cancer Guidelines for mHSPC into clinical practice; and novel decision-making tools for healthcare professions to use with patients to support informed patient decision making and drive patient engagement in their care. Priority will be given to proposals which address multiple gaps from the list and activities with a national reach and innovative dissemination models.

Eligible applicants include hospitals, academic medical centers, medical schools, national professional medical associations/societies, medical education companies, and publishers of medical and scientific information. Collaborations between organizations and within institutions are strongly encouraged.